SPOTLIGHT: Thymitaq flunks Phase III

Eximias announced that a Phase III trial of Thymitaq for unresectable Hepatocellular Carcinoma failed to hits its primary endpoint for an improved survival time compared to doxorubicin. Release

Suggested Articles

Werewolf is launching with $56 million and an approach that can cut through the toxic effects that have limited certain cancer-killing agents.

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.